Weight management for fertility preservation in endometrial cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether an app-based weight management program can help people with endometrial cancer who want to preserve their fertility. It's for those with a BMI of 25 or higher and early-stage, low-grade cancer that hasn't spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a body mass index (BMI) of 25 or higher
- You have been diagnosed with endometrial cancer that is low-grade and has not spread beyond the uterus
- You want to preserve your fertility
- You are not currently taking weight-loss medications or in another weight-loss program
- You can safely do physical activities without supervision
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a program to help endometrial cancer survivors improve their diet, physical activity, and weight. It aims to see if these changes can reduce the risk of the cancer coming back and improve overall health.
This study tests whether bariatric (weight-loss) surgery can help treat certain early, low-grade womb changes while preserving fertility. It’s mainly for people with a higher BMI who want to have children and have an early stage diagnosis confirmed by scans.
This study tests whether combining exercise with a special diet can improve how your body processes energy (metabolism) before you have surgery to remove the cancer. It is for people with early-stage endometrial cancer who haven't yet started treatment.
This study tests whether a three-month program that includes weight-loss medications and hormone therapy before surgery is better than surgery alone for women with early-stage endometrial cancer and severe obesity. The goal is to see if this approach improves surgical outcomes and overall health.
This study tests if adding a weight loss medication (tirzepatide or semaglutide) during chemotherapy helps people with early-stage endometrial cancer who are overweight or have diabetes. It aims to see if weight loss can improve treatment outcomes.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.